United Nations drug enforcement body gives global legalization a public finger wagging

The International Narcotics Control Board (INCB), a United Nations drug enforcement body, is warning the U.S., Canada, and other countries that legalizing marijuana goes against their obligations under international treaties.
The panel is responsible for enforcing anti-drug treaties and wants to remind countries that, as per three drug conventions enacted in 1961, 1971 and 1988, legalizing cannabis is prohibited unless it is for medical and scientific purposes.
That would put the eight states, and the District of Columbia, in direct opposition of the conventions because they have voted to legalize the use of marijuana for adult recreational use. So too has the country of Uruguay, and Canada is close behind with Prime Minister Trudeau pledging that recreational pot will be available to of-age adults as early as spring 2017.
The INCB is unhappy with the developments, but there seems to be little they can do to apply the brakes. In a report released last Thursday, they say, “In its discussions with the Government of the United States, the Board has continued to reiterate that the legislative and administrative measures taken by several states in the country to legalize and regulate the sale of cannabis for non-medical purposes cannot be reconciled with the legal obligation.”
“The limitation of the use of drugs to medical and scientific purposes is a fundamental principle that lies at the heart of the international drug control framework, to which no exception is possible and which gives no room for flexibility. The Board urges the Government to pursue its stated objectives — namely the promotion of health, the protection of young people and the decriminalization of minor, non-violent offenses — within the existing drug control system of the Conventions.”
The board reminds governments considering measures for opening up a recreational cannabis market that they must abide by the reporting and licensing obligations under international drug control treaties, like making sure that marijuana for medical purposes programs is carried out with competence, knowledge, and supervision. But for now, they are left merely wagging a public finger and it’s unclear whether the US and other countries feel any pressure to change their legalization plans.

11 U.S. senators ask Attorney General Jeff Sessions him to respect state marijuana laws

A letter, sent to Attorney General Jeff Sessions, requests the Department of Justice (DOJ) to uphold all existing enforcement policy regarding states that have voter-approved marijuana laws.
The bipartisan group of U.S. Senators, included in the undersigned:

  • Elizabeth Warren (D-Mass.)
  • Lisa Murkowski (R-Alaska)
  • Patty Murray (D-Wash.)
  • Ron Wyden (D-Ore.)
  • Jeff Merkley (D-Ore.)
  • Maria Cantwell (D-Wash.)
  • Ed Markey (D-Mass.)
  • Brian Schatz (D-Hawaii)
  • Catherine Cortez Masto (D-Nev.)
  • Cory Booker (D-N.J.)
  • Michael Bennet (D-Colo.)

The letter was inspired by White House Press Secretary Sean Spicer’s remarks during a briefing on February 23rd, namely his statement that “greater enforcement” would be applied to the states that have legalized cannabis for adult use.

“It is essential that states that have implemented any type of practical, effective marijuana policy receive immediate assurance from the DOJ that it will respect the ability of states to enforce thoughtful, sensible drug policies in ways that do not threaten the public’s health and safety,” the senators wrote. “This ensures that state infrastructure, including tax revenue, small businesses, and jobs, can be protected; DOJ resources can be used most effectively; and most importantly, that marijuana can be properly regulated to improve public health and safety.”

Read the full text here.
The letter mentions 2013’s “Cole Memorandum,” which provides an outline for how state and federal laws will interact regarding marijuana use and other marijuana-related activities. The enforcement Spicer hints at, could affect the eight states—Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon, and Washington, plus the District of Columbia—who have already passed laws allowing for the recreational use of marijuana despite it being illegal on a federal level.

Jamaican Scientists Discover Surprising Effect of Cannabidiol on Hepatitis C Virus

A group of scientists, led by Jamaican cancer researcher Dr. Henry Lowe, have uncovered a hopeful breakthrough in the in-vitro treatment of the hepatitis C virus (HCV)—using cannabis-derived cannabidiol (CBD) oil. Dr. Lowe’s team, working from the University of the West Indies (UWI) announced that CBD is destructive to the virus.
The HCV is blood borne and most prevalent in communities where sharing drug injections is common; it spreads through inadequate sterilization of medical equipment in hospital settings or through sexual contact. There is currently no vaccine for HCV, although the World Health Organization (WHO) does recommend education, counseling, and antiviral therapy for those already affected, along with regular monitoring for liver failure, liver cirrhosis, and cancer. WHO estimates that 130-150 million people globally have chronic HCV and hepatitis C-related liver diseases claims around 700,000 people each year.
“This discovery, which has fantastic potential for the future, is especially crucial for people in developing countries, because there is a drug which was developed for hepatitis C treatment, but it’s over $85,000 per treatment, and very few people in the developing world can afford this,” Dr. Lowe told the Jamaica Observer in a recent interview. “So it is very important that we find less expensive means of treatment, and that is why this discovery and its potential to manage this disease is so important.”
In America, medical-grade CBD oil can run anywhere between $10 to thousands of dollars. For patients in developing countries, this form of treatment is not viable because the manufacturing, distribution, and administration of CBD treatment would be too expensive for most patients.
The challenges of treating patients, however, should completely distract from the incredible discovery of the effects CBD has on eradicating the hepatitis C virus. This groundbreaking new study could create avenues where there was none before, and help pave the way for easier access to a much-needed treatment.

gl wr

Grow Lights: How to Choose the Right One

It is tempting to believe that there is such thing as the perfect grow light. A single radiant source that simply out performs everything else out there. Such a light does not exist at the moment but we have a few options. Even sunlight (the full spectrum, nuclear powered, plasma-based grow light in the sky) can damage plants if the rest of their environment is not well suited to them. Cultivators have to choose the right grow light for the right situation.
There are a few key considerations when debating between the most common lighting methods available. Using good old sunlight should work if you live anywhere near the equator but for those in the north or south need to rely on artificial means if they want to produce all year. Different growing techniques lend themselves to different setups as well.
Plasma, Induction, Ceramic Metal Halide, there are a lot of variations when it comes to lighting but for todays discussion we will be limiting the conversation to the three most popular methods. The lights we will discuss are easily obtainable, proven effective and utilized across the industry as the benchmarks that all others must compare to. There is a bit of variation within each category but they all function similarly (although you may need more than a wall socket for some).

Cultivators must consider the size of their garden.

Using a 1000-watt grow light in a two-foot by four-foot closet is generally wasteful and can lead to a lot of unnecessary problems like overheating. On the other hand, trying to cover a commercial garden with a 40,000 sq. ft. canopy in Compact Florescent Lights (CFL) won’t produce the same level of production as other lighting methods.
Growers working with small spaces need to prioritize heat dissipation over light penetration. While higher wattage lights provide more energy for your plants to work with, if the heat they produce is too much, it can stunt the plants growth. Using Compact Florescent (CFL) ballasts over High Pressure Sodium (HPS) or Metal Halide (MH) options can reduce heat buildup in small spaces while Light Emitting Diode (LED) ballasts provide a balanced mix of heat and light at a higher price point.
If you are growing more than 2-3 plants and have enough space for dedicated heat exhaust ducting, an HPS or MH light might be the right solution. The extra space needed to process the heat given off by these lights is made up for in high production levels. There are several sizes ranging from 150 up to around 1000 watts and each is designed to cover a different sized area.

Complexity is also a major consideration with grow lights.

There is a lot more to growing dank herb than sticking a seed in the ground and waiting for mother nature to work her magic. Top producers monitor every element of their operation with grow logs and performance metrics. Most growers can get away with going by eye and only measuring when they must but that won’t produce those head-sized colas that win competitions or get featured on the cover of High Times.
Adjusting CO2 generators, maintaining air conditioners and dehumidifiers, setting timers, calibrating sensors and monitoring schedules are all part of a commercial operation and can quickly add layers of complexity to a seemingly simply project. Getting the most advanced or largest lights possible may add extra layers of complexity like running exhaust ports, vent fans and electrical lines.
Having to install an extra circuit breaker is pretty frustrating but having to get the power company to upgrade the lines and transformers heading to your place in order to put in extra HPS lights can run into the tens of thousands of dollars. Using LED lights may have a higher initial investment cost (making quality versions expensive) but the energy savings add up over time.grow light

Budget is always important with grow lights.

Sometimes bigger isn’t better. If all you are doing is looking to offset the cost of buying cannabis, getting a massive light and converting the garage into a clean room worthy of NASA may not be the best route. A low cost (albeit moderate output) closet operation may work better, especially if you don’t consume only the freshest of rosin.
There are tons of options on the market for a small space grow operation with everything in a single kit. The kits normally come with a light, maybe a few pots or hydroponic bays, and they actually work pretty well (in general). They are more expensive than building it yourself but offer significantly higher quality than most people can cobble together on their own. If your goal is to make money, customization is the name of the game.
Installing LED lighting in an industrial in-door grow operation is almost a must. The initial cost is more than offset by the increased operational life of the ballasts along with the drastic (up to 30%) savings on energy. Industrial and commercial operations may still utilize CFL lights for seedling growth given the low overall cost of operating fluorescents.

When it all comes down to performance, a leader emerges.

In the end, we all want the best bang for our buck. CFL’s are great for seedlings/clones but not great for vibrant vegetative/flowering growth. Their low operating temperature also makes using them fairly basic. A low-cost alternative to LED’s for small-scale growers, CFL’s offer a solid base of performance to work up from.
HPS and MH lights offer greater output than CFL’s and are best for medium to large operations. They are specialized to vegetative and flowering and scale well for larger operations. The excess heat HPS and MH light produce compared to other options needs to be dealt with through specialized ducting or increased air conditioning but many ballasts offer specialized ports to make this easier for large strings of grow lights.
LED grow lights offer the highest performance of any grow light option but also come with the highest cost. While they don’t require the ducting of the HPS and MH lights, LED’s provide as intense of a light as any other option.  In addition to being the right intensity, LED’s require far less maintenance with a projected operating life measured in years, not months.

What is your end goal?

We have only toughed on the surface of grow lights and how to choose between them. If you want to get started quickly and easily, look into an assembled unit. It makes all the difference to have a station ready for you and not have to make all the little decisions yourself. Once you get the feel of things, you will likely be able to work with the prebuilt to fit your preferred style of growing until you are ready to do things a little bigger.
If your goal is to make money and you are just getting started, investing in HPS and MH lighting for vegetative growth and flowering along with some CFL may be the right call. Their overall cost is doable and they provide a great end product with a few extra considerations.  This is the most common setup for small to medium indoor growers looking to turn a profit.
If money is no object or you are working on a massive scale, LED lights provide the best returns over time. With minimal energy drain compared to other lights and the low operating temperature makes the energy savings a real consideration. Many units can also provide full spectrum light or specialized wavelengths for different plant cycles making them more versatile than the HPS and MH which must be switched between cycles.
Let us know what you chose to light your garden and why in the comments section. Thanks for reading.

Adult Use Cannabis Industry is on Tenterhooks After Spicer's Comments

With products that rival that of fine wine, high-end health, and wellness brands and gourmet foods that are fit for a gift basket, this controversial plant is already a big business in the US as more states make it mainstream. However, the new Trump administration is leaving those in the recreational marijuana industry to feel extremely nervous.
Last Thursday, White House press secretary Sean Spicer put the industry on tenterhooks by telling reporters that under President Donald Trump and Attorney General Jeff Sessions, the U.S. Department of Justice will administer “greater enforcement” of the recreational market, also referred to as “adult use” cannabis.
Spicer states, “I think there’s a big difference between medical marijuana, which states have allowed in accordance with the appropriations rider, have set forth a process to administer and regulate that usage, versus recreational marijuana and that’s a very, very different subject.”
The cannabis industry is in flux—federally, it’s legal but each state is in charge of its respective law—but that hasn’t stopped marijuana producers, processors, and dispensary owners from creating successful brands and products for the occasional user. In 2016, the legal market for medical and recreational cannabis combined reached almost $7 billion in the United States, which may have lulled some advocates into a sense of security that the marijuana legalization bell cannot be unrung. Arcview Market Research, which describes cannabis as the “fastest growing industry in the world,” expects revenue to increase to more than $21 billion by the end of Trump’s first term in office. How is Congress is responding to the growing popularity of marijuana? Four members have already formed a bipartisan “Cannabis Caucus” to banish conflicting laws between state and federal governments so that the entire country can capitalize on the growing industry.
Those already invested in the recreational side of the marijuana business, or hoping to enter it, must now wait for news on what will happen next.

celeb w

Celeb Cannabis Companies Vy to be First for Trademarks

What do country singer Willie Nelson, Snoop Dogg, Bob Marley, Whoopi Goldberg and Hunter S. Thompson have in common? Not only are they all icons in their own right but they may soon be trademarked, or at least their pot products will be. They are just a handful of an expanding number of celebs who are (or were) marijuana advocates and regular smokers who themselves, or their still-living relatives, have an eye on the burgeoning pot market.
Because marijuana is illegal under federal law, the U.S. Patent and Trademark office won’t issue trademarks to protect marijuana brands, so marijuana companies that can afford it—like investor-backed celebrity brands—are turning to state lawmakers for help.
Enter Rob Bonta, a Democratic assemblyman from Alameda, who introduced a bill that would grant cannabis companies state trademarks. The bill could ban marijuana billboards near freeways and provide money to develop standards for testing impaired drivers. Law enforcement officials who opposed the legalization of recreational pot have yet to take a position on this motion.
The pot-loving celebrities mentioned above have fame and backstory with the drug to help them get attention in this matter, including the children of the late Bob Marley. The reggae singer was at the forefront of the global legalization movement and now, backed by a Seattle venture capital firm, so is his oldest daughter. She launched Marley Natural back in in 2014 and the products already are available in California medical dispensaries.
Before any trademarks are granted, California’s regulators must first decide who will receive the first licenses to grow, distribute and sell recreational marijuana. Those who are already cleared to sell medical marijuana in California could be the first in line for the trademarks. Right now, those regulators are busy working with growers and sellers right now to get California’s adult-use pot market launched; the race is on to issue all the necessary licenses by early 2018.

weed drive

Accidents and the Dangers of Driving on Weed

Most people have been taught that alcohol increases the risk of accidents.

Smoking and driving can get you a DUI for an accident even in states where cannabis is legal. Current state laws for marijuana have focused on regulating it like alcohol while on the road. This is especially true when it comes to consuming and driving. Yet evidence of marijuana’s culpability in on-road accidents is difficult to prove.
Many states have reduced penalties for cannabis related crimes over the last few years. Yet as states continue to loosen regulations on marijuana safety, law enforcement is struggling to figure out how to establish a legal limit for drivers. They have focused on setting a blood-content test just like the .08 limit for alcohol.
A new study shows the challenges in accurately testing drivers.
One of the most difficult parts of testing is developing a threshold for what’s considered too high to drive. The conductors of the study concluded that “THC concentrations drop rapidly during the time required to collect a blood specimen in the U.S., generally within two to four hours.”
The low amount of time cannabis remains active for oral tests using the drivers’ saliva make it harder to fail than traditional tests. Saliva tests can be done roadside without a long wait but researchers found oral tests don’t provide “a precise measure of the level of impairment.”
Politicians are hesitant to implement concentration-based cannabis-driving legislation because it might ” unfairly target individuals not acutely intoxicated, because residual THC can be detected in blood for up to a month of sustained abstinence in chronic frequent smokers.” Depending on the direction that the new Attorney General Jeff Sessions takes the Justice Department over the coming years, detecting residual cannabinoids may be more important than registering intoxication.

Smoking weed is not safe while driving.

Cannabis intoxication has been shown to mildly impair a drivers psychomotor skills. It doesn’t appear to be severe or long lasting though. In driving simulator tests, this impairment was typically manifested by decreasing driving speed and needing more time to respond to emergency situations.
Yet this impairment does not appear to play a significant role in on-road traffic accidents. A review of seven different studies involving 7,934 drivers showed in 2002, “Crash culpability studies have failed to demonstrate that drivers with cannabinoids in the blood are significantly more likely than drug-free drivers to be culpable in road crashes.” And it’s not like people haven’t tried to prove a link either.
A Massive body of research exists that explores the impact of marijuana on psychomotor skills and actual driving performance. Researchers have done driving simulator studies, on-road performance studies, crash culpability studies, and reviews of the existing evidence. To date, the result of this research has shown how mildly cannabis affects driving abilities but that won’t stop the cops from hauling you off for having it in your system if you get in an accident.

Bad accidents

Marijuana has a measurable yet relatively mild effect on psychomotor skills.

Yet it does not appear to play a significant role in vehicle crashes, particularly when compared to alcohol. Researchers conducting a study for the National Institute on Drug Abuse said alcohol “significantly increased lane departures/minimum and maximum lateral acceleration”. Cannabis did not have the same correlation between consumption and decreased performance.

Researchers for the Highway Traffic Safety Administration funded study concluded Cannabis-influenced drivers are better able to measure their intoxication “may attempt to drive more cautiously to compensate for impairing effects, whereas alcohol-influenced drivers often underestimate their impairment and take more risk.”

People keep studying the link between cannabis, alcohol and car accidents.

The prevalence of both alcohol and cannabis use and the extreme morbidity associated with car crashes has lead to repeated research on the link between the two. According to another study, “drunk drivers are involved in 25% of motor vehicle fatalities, and many accidents involve drivers who test positive for cannabis.”
The researchers say that while both alcohol and cannabis impair performance in a “dose-related fashion” the “effects of cannabis vary more between individuals than they do with alcohol because of tolerance, differences in smoking technique, and different absorptions of Δ9-tetrahydrocannabinol (THC), the active ingredient in marijuana.”
The effects of a cannabis “high” vary according to dose but are more pronounced with highly automatic driving functions than with more complex tasks.” Basically making it easier to focus on a plan than instinctively react to something. With alcohol the opposite pattern of impairment is produced and people get distracted easier.

Cannabis and alcohol have a synergistic effect.

Because of an increased awareness that they are impaired, “marijuana smokers tend to compensate more effectively while driving than drunks” by utilizing a variety of strategies. Mixing marijuana with alcohol removes the ability to use such strategies as the two substances increase the potency of the other when mixed.
Cannabis and alcohol work on many of the same levels in the brain and both inherently affect chemical production in the brain. Mixing cannabis and booze will amplify the effects of both and can lead to serious repercussions. While studies have been inconclusive regarding whether cannabis use causes an increased risk of accidents; in contrast, unanimity exists that alcohol use increases the risk of crashes.
In addition, the risk from driving under the influence of alcohol and cannabis together is higher than the risk of driving under the influence of either alone. One study even recommends that patients who smoke cannabis wait several hours before driving, and avoid combining the two drugs.

Even schools have studied how dangerous driving while high is.

The first study to analyze the effects of cannabis on driving was conducted by Researchers at the University of Iowa’s National Advanced Driving Simulator, sponsored by National Highway Traffic Safety Administration, National Institute of Drug Abuse, and the Office of National Drug Control Policy.
The researchers found that cannabis use caused almost no impairment. The impairment that it did cause was similar to the change observed while under the influence of a legal alcohol limit. They basically couldn’t get cannabis to impair driving as much as one beer.
They tested impairment mainly with a simulator. “Once in the simulator—a 1996 Malibu sedan mounted in a 24-feet diameter dome—the drivers were assessed on weaving within the lane, how often the car left the lane, and the speed of the weaving. Drivers with only alcohol in their systems showed impairment in all three areas while those strictly under the influence of vaporized cannabis only demonstrated problems weaving within the lane.”

More research is needed to find the right limits.

All these study’s findings show that alcohol is a much more dangerous drug than cannabis yet regulated in a more relaxed manner. While driving while under the influence of cannabis can still get you locked up, it is unclear how dangerous it is. More research is needed to show exactly how much cannabis should be legally allowable but for the time being, driving after consuming any cannabis remains illegal.
Until the whole world switches over to autonomous vehicles and we don’t have to worry about driver error any more, people are still going to get into accidents (sober or not). It is best not to contribute to the problem and simply don’t drive while high. You never know when you might need to instinctually react to something in your lane. Thanks for reading.


Study: Academically inclined students more likely to try pot (and alcohol)

Smart students tend to experiment more with drugs and alcohol, but James Williams and Gareth Hagger-Johnson, co-authors of a new study, point out some of the reasons behind the phenomenon. The study, published Wednesday in the British Medical Journal Open, found that academically gifted teens are less likely to smoke cigarettes and more likely to drink alcohol and smoke pot compared with those with lower scores.
Wanting to understand more about a recent decrease in the number of teens who were admitting to trying tobacco, alcohol, and cannabis (down 4%, 6% and 9% respectively from the figures in 2004), Williams and Hagger-Johnson surveyed more than 6,000 students from public and private schools across England. They tracked each student’s use of tobacco, alcohol, and cannabis from age 13 or 14 until age 19 or 20, as well as their academic scores.
What they found was that during their early teens, were slightly more likely to say they used cannabis and less likely to use tobacco and alcohol. Later on, those same high-scoring students were more than twice as inclined to drink alcohol but less likely to binge-drink. The highest-scoring pupils were almost twice as likely to use cannabis regularly and 50% more likely to use it occasionally compared with lower-scoring teens.
Williams and Hagger-Johnson drew a few conclusions from their study. One was that cognitive ability indicates an openness to new experiences, which paired with boredom due to a lack of stimulation in class. Another was that smart teens run with older peers who were already into their phase of experimenting with substances. Drinking patterns, they say could be related to the socioeconomic status of their parents, stating that “parental influence, since parents with high cognitive ability and socioeconomic status are known to drink alcohol more regularly.”
Dr. Amir Levine, a psychiatrist and assistant professor at Columbia University Medical Center, finds the results interesting but points out the necessity “to differentiate between substance experimentation and problem drug use.” He adds, “We usually think about youth who are not doing well in school as the ones that are prone to alcohol and drug use.”

m mari

New Conditions Could be Added to New Jersey's Medical Marijuana Program

Medical marijuana may become an option for those in New Jersey who suffer from chronic pain, thanks to some emotional testimony that took place before a Health Department advisory panel at the War Memorial last Wednesday. The measure would expand the standing list of about a dozen ailments that already qualify for treatment using therapeutic cannabis, which includes terminal cancer, MS, and epilepsy.
During the three-hour hearing, more than 20 patients testified after submitting petitions, references to health studies, and even their own doctor’s recommendations. The Health Department says it received 68 requests last year for about 20 new conditions to be considered, including lupus, autism, osteoarthritis, and opioid addiction disorder.
Chairing the panel is a professor of anesthesiology, Alex Bekker, who states, “I feel there is sufficient evidence to add chronic pain and migraines and fibromyalgia, all under the one umbrella of chronic pain.” Bekker feels optimistic about his panel being for the measure and that adding chronic pain to the list will have more benefit than risk. He conceded the drug’s palliative effects, confirming that there is “sufficient evidence. . . .that marijuana can be very helpful” for any chronic pain.
The panel now has 60 days to submit their report that Bekker, followed by a five-month public review session. Once that is through, a final determination from DOH Commissioner Cathleen Bennett will come sometime in October. The New Jersey Medicinal Marijuana Program is now seven years old, but this is the first time that the panel held a public forum to discuss adding new conditions.
On the eight month waiting period, Sen. Joseph Vitale (D-Middlesex), chairman of the Health Committee, says “That’s far too long when evidence from other states is clear on the efficacy of treating (chronic pain from) certain disorders and diseases.”

Reports says Marijuana Will Create More Jobs Than Manufacturing By 2020

If it’s jobs that President Trump wants to conjure up during his time in office, then he should look no further than the cannabis cash crop to create more jobs than manufacturing by 2020.
That number comes from New Frontier Data, an authority in business intelligence for the cannabis industry, projects that the legal marijuana market will create 283,422 jobs over the next 13 years. That’s more than the Bureau of Labor Statistics expects will come from industries like manufacturing, utilities, and even government. In fact, the BLS says that the manufacturing sector will shrink by about 814,000 jobs over the next 17 years, utilities by 47,000, and government by 383,000 positions.
“These numbers confirm that cannabis is a major economic driver and job creation engine for the U.S. economy,” said Giadha Aguirre De Carcer, Founder and CEO of New Frontier Data. “While we see a potential drop in total number of U.S. jobs created in 2017, as reported by Kiplinger, as well as an overall expected drop in GDP growth, the cannabis industry continues to be a positive contributing factor to growth at a time of potential decline. We expect the cannabis industry’s growth to be slowed down to some degree in the next 3 to 5 years, however with a projected total market sales to exceed $24 billion by 2025, and the possibility of almost 300,000 jobs by 2020, it remains a positive economic force in the U.S.”
In 2016, the legal cannabis market was worth an estimated $7.2 billion in 2016, and that number is only growing at a compound rate of 17%, according to projections. Sales will go from $4.7 billion in 2016 to $13.3 billion in 2020, in medical cannabis alone. On the adult-use recreational end, those sales are expected to reach $11.2 billion by 2020.
New Frontier’s projections are based on the markets that are already part of legal initiatives, meaning the 28 states with some form of medical or adult-use marijuana for sale. The numbers do not include any additional states that may pass legalization measures between now and 2020, though the number of revenue and jobs would significantly increase if more states expand their legalized cannabis programs.